Researchers conducted a clinical trial at six hospitals in Israel, Greece and Italy. They studied adults with bacteraemia, ventilator-associated pneumonia, hospital-acquired pneumonia or urosepsis caused by carbapenem-non-susceptible Gram-negative bacteria. The study participants were randomly assigned to receive intravenous colistin or colistin with meropenem. The study, conducted between Oct. 1, 2013, and Dec. 31, 2016, included 406 patients.
Here are four study findings:
1. Eighty-seven percent of the patients had pneumonia or bacteraemia.
2. Seventy-seven percent of the infections were caused by Acinetobacter baumannii.
3. Researchers found no significant difference between the colistin monotherapy group and the combination therapy group with regard to clinical failure at 14 days after randomization.
4. Combination therapy increased the incidence of diarrhea and decreased the incidence of mild renal failure among patients.
More articles on healthcare quality:
Last Parkland shooting victim in critical condition recovers at Broward Health North
Salmonella outbreak tied to frozen coconut likely over, CDC say
Senators request $1B toward universal flu vaccine development
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.